Moderna, Inc.
Close on Nov 2, 2026Market cap $88.16BP/E –Yield –
Moderna Recognized from beginning deferred revenue by Quarter
Recognized from beginning deferred revenue — Product sales ($M) ($M)
Moderna Recognized from beginning deferred revenue: $171M in Q2 2026, up 103.6% from a year earlier.
Where the Q2 2026 figure comes from
Calculated from reported figures: quarter = year-to-date − previous year-to-date (cash flow statement)
Source: Form 10-Q (filed 2026-07-31) ↗
Reported in Form 10-Q / 10-K Note 2 (Contract Liabilities).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Recognized from beginning deferred revenue — Product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 171 | +103.6% | Form 10-Q (filed 2026-07-31) ↗ |
| Q1 2026 | Mar 31, 2026 | 0 | – | Form 10-Q (filed 2026-05-01) ↗ |
| Q4 2025 | Dec 31, 2025 | 24 | +2,300.0% | Form 10-K (filed 2026-02-20) ↗ |
| Q3 2025 | Sep 30, 2025 | 0 | -100.0% | Form 10-Q (filed 2025-11-06) ↗ |
| Q2 2025 | Jun 30, 2025 | 84 | -53.8% | Form 10-Q (filed 2025-08-01) ↗ |
| Q1 2025 | Mar 31, 2025 | 0 | -100.0% | Form 10-Q (filed 2025-05-01) ↗ |
| Q4 2024 | Dec 31, 2024 | 1 | -99.7% | Form 10-K (filed 2025-02-21) ↗ |
| Q3 2024 | Sep 30, 2024 | 28 | -65.0% | Form 10-Q (filed 2024-11-07) ↗ |
| Q2 2024 | Jun 30, 2024 | 182 | +122.0% | Form 10-Q (filed 2024-08-01) ↗ |
| Q1 2024 | Mar 31, 2024 | 14 | -68.9% | Form 10-Q (filed 2024-05-02) ↗ |
| Q4 2023 | Dec 31, 2023 | 308 | +616.3% | Form 10-K (filed 2024-02-23) ↗ |
| Q3 2023 | Sep 30, 2023 | 80 | -87.4% | Form 10-Q (filed 2023-11-03) ↗ |
| Q2 2023 | Jun 30, 2023 | 82 | +3.8% | Form 10-Q (filed 2023-08-03) ↗ |
| Q1 2023 | Mar 31, 2023 | 45 | -97.4% | Form 10-Q (filed 2023-05-04) ↗ |
| Q4 2022 | Dec 31, 2022 | 43 | -97.9% | Form 10-K (filed 2023-02-24) ↗ |
| Q3 2022 | Sep 30, 2022 | 633 | -81.8% | Form 10-Q (filed 2022-11-03) ↗ |
| Q2 2022 | Jun 30, 2022 | 79 | -95.3% | Form 10-Q (filed 2022-08-03) ↗ |
| Q1 2022 | Mar 31, 2022 | 1,755 | -60.7% | Form 10-Q (filed 2022-05-04) ↗ |
| Q4 2021 | Dec 31, 2021 | 2,042 | – | Form 10-K (filed 2022-02-25) ↗ |
| Q3 2021 | Sep 30, 2021 | 3,470 | – | Form 10-Q (filed 2021-11-04) ↗ |
| Q2 2021 | Jun 30, 2021 | 1,678 | – | Form 10-Q (filed 2021-08-05) ↗ |
| Q1 2021 | Mar 31, 2021 | 4,467 | – | Form 10-Q (filed 2021-05-06) ↗ |
Cite this data
StockData. (2026). Moderna Recognized from beginning deferred revenue ($M), quarterly Q1 2021–Q2 2026 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/def-rev-rec-prod
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.